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A boy with X-linked agammaglobulinemia experienced progressive global motor decline, cerebellar syndrome,
and epilepsy. All standard polymerase chain reactions for neurotropic viruses were negative on cerebrospinal
fluid and brain biopsy. Next-generation sequencing allowed fast identification of a new astrovirus strain (HAstV-
VA1/HMO-C-PA), which led to tailor the patient’s treatment, with encouraging clinical monitoring over 1 year.
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INTRODUCTION
Viral encephalitis is a major cause of morbidity and mor-
tality in patients with inherited primary immunodeficiency
(PID) such as X-linked agammaglobulinemia (XLA) [1].
Encephalitis of unknown etiology also constitutes a
major challenge, in particular in immunocompromised pa-
tients, despite extensive laboratory testing including cul-
tures, reverse transcription-polymerase chain reaction
(RT-PCR) and amplicon sequencing [2, 3]. Failure to iden-
tify the etiology in infectious encephalitis impairs or delays
appropriate therapeutics and increases morbidity and mor-
tality associated with these diseases, notably in patients
with PIDs. Infectious encephalitis of unknown etiology
probably account for most of undiagnosed progressive cog-
nitive decline in XLA patients. Next-generation sequencing
(NGS) is becoming an alternative diagnosis tool for infec-
tious diseases [4]. In this study, we report the case of a boy
with unidentified encephalitis in the context of XLA in
which NGS led to the identification of a new astrovirus
strain related to the VA1/HMO-C group and allowed
tailored therapy, with encouraging clinical monitoring
over 1 year.
CASE REPORT
A 14-year-old boy with XLA, a genetic disorder affecting
B-cell differentiation due to hemizygous mutation in the
Bruton tyrosine kinase coding gene, was admitted to the
immunology unit with a progressive cognitive decline
and recurring seizures over 1 year. He had no peripheral
B cell and showed a profound agammaglobulinemia. He
was put on substitutive polyvalent intravenous immuno-
globulins (IVIG) every 3 weeks and was well until, at 10
years of age, he started to display myoclonic epilepsy
with no viral finding (cerebrospinal fluid [CSF], blood, spu-
tum, and stools). A cognitive impairment was noted over
the last 4 years (loss of 30 points of Intelligence Quotient
[Wechsler Intelligence Scale for Children, WISC-IV]). He
was unable to read or write, and his speech was impaired.
Clinical examination found ataxia, erratic myoclonies, and
dysarthria. In June 2013, brain magnetic resonance
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imaging (MRI) showed diffuse cortical-subcortical brain
atrophy and periventricular hypersignals (Figure 1A).
Electroencephalography revealed irregular slow-wave ac-
tivity associated with bilateral frontotemporal spikes but
no epileptic discharges. Cerebrospinal fluid analysis was
normal for white cell count, for glucose and protein
concentrations, and was negative by real-time PCR and
RT-PCR for a comprehensive list of neurotropic viruses
(Supplementary Table S1). Brain biopsy was performed in
the right frontal lobe in February 2014. Histologic findings
were consistent with acute pan-encephalitis (Figure 1B),
and all standard PCR and RT-PCR for neurotropic viruses
Figure 1. The clinical case is illustrated. (A) Results of brain magnetic resonance imaging (MRI) in T2-weighted sequences performed on June 2013 (1) and on February
2014 after brain biopsy (2), showing global white and gray matter atrophy and periventricular hypersignals. Brain MRI performed on September 2014 (3) showed no
progression in brain atrophy or increasing in periventricular hypersignals. (B) Results of brain biopsy showing the following: (1) microglial nodules (arrow) and peri-
vascular infiltrates (arrow heads) in the cortex and white matter (hematoxylin and eosin stain, bar = 100 μm); (2) IBA1 immunohistochemistry confirming diffuse micro-
glial activation (WAKO rabbit polyclonal anti-IBA1, 1:500) (bar = 100 μm). Perivascular cuffs of mononuclear cells include T lymphocytes (3) CD3+ (Ventana
monoclonal rabbit antibody 1:500) and (4) CD8+ (FLEX ready-to-use monoclonal mouse antibody) (bar = 50 μm). There is no feature of Creutzfeldt-Jakob disease.
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were negative on this biopsy sample (Supplementary
Table S1). Total RNAs, as a signature of viral, bacterial, fun-
gal, or protozoan gene expression, were deep sequenced by
NGS and analyzed. Large fragments of an astrovirus genome
were identified, showing high levels of homology with the
VA1/HMO-C clade (a clade distant to those screened by
standard RT-PCR). The complete genome was obtained,
and this new strain was named HAstV-VA1/HMO-C-PA.
It was striking to discover that HAstV-VA1/HMO-C-PA is
closely related to 3 astrovirus strains that have been reported
recently in human cases of encephalitis, in different immuno-
compromised contexts including XLA [5–7]. Specific
RT-PCR were designed and were positive on the brain biop-
sy sample (Supplementary Figure S3) but not on the CSF pre-
viously ( June 2013) and concomitantly (March 2014)
sampled (for detailed information on methods and results,
see Supplementary Data). This virus identification led to
an adaptation of treatment and prescription of high-dose
IVIG 1 g/kg per day, quickly tapered to 1 g/kg twice and
then once a week due to mild clinical intolerance, and 3
bolus of methylprednisolone (1 g/1.73 m2 for 3 consecutive
days). The patient also received intravenous ribavirin for
7 days (30 mg/kg per day, then 15 mg/kg every 6 hours for
4 days, followed by 8 mg/kg every 8 hours for 3 days) and
then daily oral ribavirin and 50 μg pegylated interferon
(PEG-IFN) alpha-2b per week. He is currently under daily
oral ribavirin (800 mg/day, which was later adjusted based
on hematologic tolerance) and 50 μg PEG-IFN alpha-2b
and 1 g/kg IVIG per week. At month 12 of follow-up, pro-
gression in motor behavior and mild memory improvement
has been noted. MeasuredWISC-IV was stable and epilepsy
was controlled. Brain atrophy and periventricular hypersig-
nals remained stable upon brain MRI control.
Ethic Statement
Next-generation sequencing analysis was performed on the
brain biopsy done for standard diagnostic. Written consent
was obtained from the parents for his inclusion in the
“Pathodisc” study, which was aimed at identifying patho-
gens in infectious syndromes of unknown etiology byNGS.
The Pathodisc study was approved by the French Ethical
Committee, CPP Ile de France IV, including College I and
College II (on January 26, 2010 under the code 2009/
31NICB), and declared to the French Research Ministry
under the code DC 2009–1067 collection 25, amendment
to the file 2008–68, collection n°1, following the French
regulation. It was also approved by the French Privacy
Agency (Commission de l’Informatique et des Libertés)
on August 11, 2011. The samples were managed by the
ICAReB platform, with regards to bio-resource ethical
compliance, transport, registering and coding.
DISCUSSION
The Astroviridae family comprises nonenveloped, positive
sense, single-stranded enteric RNA viruses, typically 28–
30 nm in diameter. One of the genuses, Mamastrovirus,
comprises viruses infecting mammals including a clade cor-
responding to human astroviruses 1–8 (HAstVs 1–8)
(Figure 2B) [8]. Another clade, closer to porcine, mink,
and ovine astroviruses, has been identified in a case of
human gastroenteritis [9] and is referred to as the VA1/
HMO-C clade. In 2010, a member of this clade was iden-
tified as responsible for persistent brain infection leading to
dementia and death in a boy with XLA in the United States
[5], and in 2015 2 independent cases coming from the
United Kingdom have supported the involvement of VA1/
HMO-C strains in 2 other fatal cases of encephalitis [6, 7].
Thus, we hypothesize that infections by astroviruses be-
longing to the clade VA1/HMO-C, thought to be highly
prevalent in the human population [10], remain under-
diagnosed and might therefore account for a part of
nonidentified progressive neurodegeneration in immuno-
compromised patients. Beyond the VA1/HMO-C group,
it should be noted that HAstV4 has been identified, post
mortem, in the brain tissue of a 7-month-old boy with
severe combined immunodeficiency in the context of dis-
seminated multiorgan infection [11]. More generally,
astroviruses have begun to be recognized as causative
agents of encephalitis and neurological disorders in cattle
[12,13] and mink [14], although not belonging to the
VA1/HMO-C group, which may suggest different or even
species-specific mechanisms of neurotropic infection.
Therefore, astroviruses, and in particular members of the
VA1/HMO-C clade, complete the list of enteric viruses
that, like some enteroviruses (poliovirus vaccine strain, cox-
sackie viruses, and echoviruses) [15–17],may disseminate to
the central nervous system despite IVIG reconstitution.
Based on other RNA-virus treatment approaches in this set-
ting [18], treatment was modified upon the diagnosis of
astrovirus infection, to include higher doses of IVIG, ribavi-
rin, and PEG-IFN alpha-2b. Mild cognitive improvement
was noted after a 12-month follow up, although it is difficult
to assess the impact of treatment on the course of the disease.
This study illustrates the strength of deep sequencing ap-
plied to the diagnosis of infectious diseases, not only in re-
vealing the presence of unpredicted infectious agents in
patients’ samples but also in identifying genetic virus vari-
ants that may not be detected by generic PCRs. This seems
particularly relevant for most RNA viruses, whose ge-
nomes are highly variable. In the present case, although
astroviruses were thought to be a possible etiology, stan-
dard PCRwas unable to detect the pathogen due its genetic
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distance from the HAstVs 1–8 clade. Even within the VA1/
HMO-C clade, variations in sequences still exist and may
be responsible for the failure of generic PCR amplification
(for an illustration, see Supplementary Figure S2). Overall,
this study is a striking illustration of (1) the limit of target-
ed, gene-specific approaches applied to the diagnosis of
viral diseases and (2) the strength of NGS, for which no
a priori on-target sequence is needed.
CONCLUSIONS
Using optimized pipelines and sequencers, results can be
delivered within a time short enough for a medical decision
Figure 2. Astrovirus identification by NGS and sequences analysis. (A) Upper part: a total of 68 reads assembled or not in contigs are mapped to the closest astrovirus
strain, astrovirus VA1 (FJ973620), to illustrate the genome coverage (see details about genome finishing in Supplementary Figure S1). Polymerase chain reaction primers
used in this study (Astro-255; SF0073/76; PA-SG-VA1) or by others (SG/VA1) are depicted in relation to their genomic location. Bottom part: percentage of identity
between strain HAstrV-VA1/HMO-C-PA and other close (HAstrV-VA1/HMO-C-UK1, HAstrV-VA1/HMO-C-UK1(a), astrovirus VA1, astrovirus SG) or more distant
(HAstrV1, MLB1) human astroviruses. (B) Phylogenic analysis based on whole genomes, showing representative astrovirus strains and highlighting the VA1/HMO-C
clade, which features HAstrV-VA1/HMO-C-PA (all accession numbers are detailed in the Supplementary Data).
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shift and clinical benefit [4]. In our case, virus identification
was obtained less than 3 days from reception of the sample.
Our results extend to viral diseases the demonstration of
the usefulness of NGS shown for bacterial diseases,
drawn from a case of neuroleptospirosis in a boy with a
severe combined immunodeficiency, for which the diagno-
sis was only established by NGS and led to a rapid and
efficient treatment [19]. Because of its increasing availabil-
ity in the clinics, NGS will probably be applied in a first
step to cases where an infectious etiology is likely despite
negative extensive search for infectious agents by all avail-
able conventional methods.
Supplementary Data
Supplementary materials are available at the Journal of the
Pediatric Infectious Diseases Society online (http://jpids.
oxfordjournals.org).
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